Target Group Reports Going Concern Doubt, Ineffective Controls, & Debt Breach Amid Deepening Losses
summarizeSummary
Target Group Inc. filed its annual report revealing substantial doubt about its ability to continue as a going concern, ineffective internal controls, and a breach of a related party loan agreement, alongside significant financial deterioration.
check_boxKey Events
-
Going Concern Warning Issued
Both the independent auditors and management have raised substantial doubt about the company's ability to continue as a going concern, citing significant working capital and accumulated deficits.
-
Ineffective Internal Controls
Management concluded that internal controls over financial reporting and disclosure controls were ineffective as of December 31, 2025, due to a lack of an overall system of internal controls.
-
Significant Financial Deterioration
The company reported a net loss of $1.36 million for 2025, a significant decline from a net income of $160,504 in 2024. Revenue also decreased from $6.59 million in 2024 to $3.88 million in 2025.
-
Breach of Loan Agreement & High-Interest Financing
Target Group Inc. breached a related party loan agreement due to missed repayments. Post-period, the company secured an additional $240,768 loan at a high monthly interest rate of 3.0146%.
auto_awesomeAnalysis
Target Group Inc.'s annual report highlights severe financial distress and operational challenges. The company's auditors and management have expressed substantial doubt about its ability to continue as a going concern, citing a worsening working capital deficit and accumulated deficit. Furthermore, management concluded that internal controls over financial reporting were ineffective, indicating significant governance issues. The company also breached a related party loan agreement and subsequently secured an additional high-interest loan, underscoring its precarious financial position and urgent need for capital. These factors collectively present a highly negative outlook for investors.
At the time of this filing, CBDY was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.